Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Midazolam via ZENEO Auto-Injector vs Syringe in Healthy Subjects
NCT05026567Phase 1Completed
- Sponsor
- Crossject
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of midazolam in status epilepticus (SE) (4 arms), sponsored by Crossject. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 36 hours, Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity at 36 hours and 1 more. Started May 2022; status: completed.
02
Drugs
midazolam
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT05026567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05026567.